Skip to content

Research at St Andrews

New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects

Research output: Contribution to journalArticle

Standard

New antituberculosis drugs, regimens, and adjunct therapies : needs, advances, and future prospects. / Zumla, Alimuddin I; Gillespie, Stephen H; Hoelscher, Michael; Philips, Patrick P J; Cole, Stewart T; Abubakar, Ibrahim; McHugh, Timothy D; Schito, Marco; Maeurer, Markus; Nunn, Andrew J.

In: Lancet Infectious Diseases, Vol. 14, No. 4, 04.2014, p. 327-40.

Research output: Contribution to journalArticle

Harvard

Zumla, AI, Gillespie, SH, Hoelscher, M, Philips, PPJ, Cole, ST, Abubakar, I, McHugh, TD, Schito, M, Maeurer, M & Nunn, AJ 2014, 'New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects', Lancet Infectious Diseases, vol. 14, no. 4, pp. 327-40. https://doi.org/10.1016/S1473-3099(13)70328-1

APA

Zumla, A. I., Gillespie, S. H., Hoelscher, M., Philips, P. P. J., Cole, S. T., Abubakar, I., ... Nunn, A. J. (2014). New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infectious Diseases, 14(4), 327-40. https://doi.org/10.1016/S1473-3099(13)70328-1

Vancouver

Zumla AI, Gillespie SH, Hoelscher M, Philips PPJ, Cole ST, Abubakar I et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infectious Diseases. 2014 Apr;14(4):327-40. https://doi.org/10.1016/S1473-3099(13)70328-1

Author

Zumla, Alimuddin I ; Gillespie, Stephen H ; Hoelscher, Michael ; Philips, Patrick P J ; Cole, Stewart T ; Abubakar, Ibrahim ; McHugh, Timothy D ; Schito, Marco ; Maeurer, Markus ; Nunn, Andrew J. / New antituberculosis drugs, regimens, and adjunct therapies : needs, advances, and future prospects. In: Lancet Infectious Diseases. 2014 ; Vol. 14, No. 4. pp. 327-40.

Bibtex - Download

@article{1e2a9e58190a45fa8bedfba8861f90ac,
title = "New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects",
abstract = "About 1·3 million people died of tuberculosis in 2012, despite availability of effective drug treatment. Barriers to improvements in outcomes include long treatment duration (resulting in poor patient adherence and loss of patients to follow-up), complex regimens that involve expensive and toxic drugs, toxic effects when given with antiretroviral therapy, and multidrug resistance. After 50 years of no antituberculosis drug development, a promising pipeline is emerging through the repurposing of old drugs, re-engineering of existing antibacterial compounds, and discovery of new compounds. A range of novel antituberculosis drugs are in preclinical development, several phase 2 and 3 trials are underway, and use of adjunct therapies is being explored for drug-sensitive and drug-resistant tuberculosis. Historical advances include approval of two new drugs, delamanid and bedaquiline. Combinations of new and existing drugs are being assessed to shorten the duration of therapy and to treat multidrug-resistant tuberculosis. There has also been progress in development of new antituberculosis drugs that are active against dormant or persister populations of Mycobacterium tuberculosis. In this Review, we discuss recent advances in antituberculosis drug discovery and development, clinical trial designs, laboratory methods, and adjunct host-directed therapies, and we provide an update of phase 3 trials of various fluoroquinolones (RIFAQUIN, NIRT, OFLOTUB, and REMoxTB). We also emphasise the need to engage the community in design, implementation, and uptake of research, to increase international cooperation between drug developers and health-care providers adopting new regimens.",
keywords = "Antitubercular Agents, Biological Markers, Clinical Trials as Topic, Drug Discovery, Drug Therapy, Combination, Humans, Immunotherapy, Medication Adherence, Research Design, Tuberculosis, Multidrug-Resistant, Tuberculosis, Pulmonary",
author = "Zumla, {Alimuddin I} and Gillespie, {Stephen H} and Michael Hoelscher and Philips, {Patrick P J} and Cole, {Stewart T} and Ibrahim Abubakar and McHugh, {Timothy D} and Marco Schito and Markus Maeurer and Nunn, {Andrew J}",
note = "Copyright {\circledC} 2014 Elsevier Ltd. All rights reserved.",
year = "2014",
month = "4",
doi = "10.1016/S1473-3099(13)70328-1",
language = "English",
volume = "14",
pages = "327--40",
journal = "Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "Elsevier",
number = "4",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - New antituberculosis drugs, regimens, and adjunct therapies

T2 - needs, advances, and future prospects

AU - Zumla, Alimuddin I

AU - Gillespie, Stephen H

AU - Hoelscher, Michael

AU - Philips, Patrick P J

AU - Cole, Stewart T

AU - Abubakar, Ibrahim

AU - McHugh, Timothy D

AU - Schito, Marco

AU - Maeurer, Markus

AU - Nunn, Andrew J

N1 - Copyright © 2014 Elsevier Ltd. All rights reserved.

PY - 2014/4

Y1 - 2014/4

N2 - About 1·3 million people died of tuberculosis in 2012, despite availability of effective drug treatment. Barriers to improvements in outcomes include long treatment duration (resulting in poor patient adherence and loss of patients to follow-up), complex regimens that involve expensive and toxic drugs, toxic effects when given with antiretroviral therapy, and multidrug resistance. After 50 years of no antituberculosis drug development, a promising pipeline is emerging through the repurposing of old drugs, re-engineering of existing antibacterial compounds, and discovery of new compounds. A range of novel antituberculosis drugs are in preclinical development, several phase 2 and 3 trials are underway, and use of adjunct therapies is being explored for drug-sensitive and drug-resistant tuberculosis. Historical advances include approval of two new drugs, delamanid and bedaquiline. Combinations of new and existing drugs are being assessed to shorten the duration of therapy and to treat multidrug-resistant tuberculosis. There has also been progress in development of new antituberculosis drugs that are active against dormant or persister populations of Mycobacterium tuberculosis. In this Review, we discuss recent advances in antituberculosis drug discovery and development, clinical trial designs, laboratory methods, and adjunct host-directed therapies, and we provide an update of phase 3 trials of various fluoroquinolones (RIFAQUIN, NIRT, OFLOTUB, and REMoxTB). We also emphasise the need to engage the community in design, implementation, and uptake of research, to increase international cooperation between drug developers and health-care providers adopting new regimens.

AB - About 1·3 million people died of tuberculosis in 2012, despite availability of effective drug treatment. Barriers to improvements in outcomes include long treatment duration (resulting in poor patient adherence and loss of patients to follow-up), complex regimens that involve expensive and toxic drugs, toxic effects when given with antiretroviral therapy, and multidrug resistance. After 50 years of no antituberculosis drug development, a promising pipeline is emerging through the repurposing of old drugs, re-engineering of existing antibacterial compounds, and discovery of new compounds. A range of novel antituberculosis drugs are in preclinical development, several phase 2 and 3 trials are underway, and use of adjunct therapies is being explored for drug-sensitive and drug-resistant tuberculosis. Historical advances include approval of two new drugs, delamanid and bedaquiline. Combinations of new and existing drugs are being assessed to shorten the duration of therapy and to treat multidrug-resistant tuberculosis. There has also been progress in development of new antituberculosis drugs that are active against dormant or persister populations of Mycobacterium tuberculosis. In this Review, we discuss recent advances in antituberculosis drug discovery and development, clinical trial designs, laboratory methods, and adjunct host-directed therapies, and we provide an update of phase 3 trials of various fluoroquinolones (RIFAQUIN, NIRT, OFLOTUB, and REMoxTB). We also emphasise the need to engage the community in design, implementation, and uptake of research, to increase international cooperation between drug developers and health-care providers adopting new regimens.

KW - Antitubercular Agents

KW - Biological Markers

KW - Clinical Trials as Topic

KW - Drug Discovery

KW - Drug Therapy, Combination

KW - Humans

KW - Immunotherapy

KW - Medication Adherence

KW - Research Design

KW - Tuberculosis, Multidrug-Resistant

KW - Tuberculosis, Pulmonary

U2 - 10.1016/S1473-3099(13)70328-1

DO - 10.1016/S1473-3099(13)70328-1

M3 - Article

VL - 14

SP - 327

EP - 340

JO - Lancet Infectious Diseases

JF - Lancet Infectious Diseases

SN - 1473-3099

IS - 4

ER -

Related by author

  1. Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection

    Kloprogge, F., Hammond, R., Kipper, K., Gillespie, S. H. & Della Pasqua, O., 13 Sep 2019, In : Scientific Reports. 9, 8 p., 13228.

    Research output: Contribution to journalArticle

  2. A tuberculosis molecular bacterial load assay (TB-MBLA)

    Sabiiti, W., Mtafya, B. A., Alferes De Lima, D., Dombay, E., Baron, V. O., Azam, K., Orascova, K., Sloan, D. J. & Gillespie, S. H., 6 Sep 2019, (Accepted/In press) In : Journal of Visualized Experiments.

    Research output: Contribution to journalArticle

  3. Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?

    Kloprogge, F., Hammond, R., Copas, A., Gillespie, S. H. & Della Pasqua, O., 25 Aug 2019, In : Journal of Antimicrobial Chemotherapy. Advance article, 7 p.

    Research output: Contribution to journalArticle

  4. Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

    Tweed, C. D., Crook, A. M., Dawson, R., Diacon, A. H., McHugh, T. D., Mendel, C. M., Meredith, S. K., Mohapi, L., Murphy, M. E., Nunn, A. J., Phillips, P. P. J., Singh, K. P., Spigelman, M. & Gillespie, S. H., 14 Aug 2019, In : BMC Pulmonary Medicine. 19, 9 p., 152.

    Research output: Contribution to journalArticle

  5. Model-based relationship between the molecular bacterial load assay and time-to-positivity in liquid culture

    Svensson, R. J., Sabiiti, W., Kibiki, G. S., Ntinginya, N. E., Bhatt, N., Davies, G., Gillespie, S. H. & Simonsson, U. S. H., 29 Jul 2019, In : Antimicrobial Agents and Chemotherapy. Early

    Research output: Contribution to journalArticle

Related by journal

  1. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

    Boeree, M. J., Heinrich, N., Aarnoutse, R., Diacon, A. H., Dawson, R., Rehal, S., Kibiki, G. S., Churchyard, G., Sanne, I., Ntinginya, N. E., Minja, L. T., Hunt, R. D., Charalambous, S., Hanekom, M., Semvua, H. H., Mpagama, S. G., Manyama, C., Mtafya, B., Reither, K., Wallis, R. S. & 9 others, Venter, A., Narunsky, K., Mekota, A., Henne, S., Colbers, A., Plemper van Balen, G., Gillespie, S. H., Phillips, P. P. J. & Hoelscher, M., Jan 2017, In : Lancet Infectious Diseases. 17, 1, p. 39-49 11 p.

    Research output: Contribution to journalArticle

  2. Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study

    Aliberti, S., Reyes, L. F., Faverio, P., Sotgiu, G., Dore, S., Rodriguez, A. H., Soni, N. J., Restrepo, M. I., GLIMP investigators & Dhasmana, D. J., Dec 2016, In : Lancet Infectious Diseases. 16, 12, p. 1364-1376 13 p.

    Research output: Contribution to journalArticle

  3. Chasing Koch's chimera

    Klatser, P., Anthony, R., Barry, C., Drobniewski, F., Hoffner, S., Niemann, S. & Gillespie, S., 1 Jan 2013, In : The Lancet Infectious Diseases. 13, 4, p. 289-291 3 p.

    Research output: Contribution to journalLetter

  4. Whole-genome sequencing for analysis of an outbreak of meticillin-resistant Staphylococcus aureus: a descriptive study

    Harris, S. R., Cartwright, E. J. P., Toeroek, M. E., Holden, M. T. G., Brown, N. M., Ogilvy-Stuart, A. L., Ellington, M. J., Quail, M. A., Bentley, S. D., Parkhill, J. & Peacock, S. J., Feb 2013, In : Lancet Infectious Diseases. 13, 2, p. 130-136 7 p.

    Research output: Contribution to journalArticle

ID: 147224141

Top